T he use of implantable cardioverterdefibrillators (ICDs) is an established ther apy for the prevention of death from ven tricular arrhythmia. 1-5 However, conventional ICDs rely on transvenous leads for cardiac sensing and defibrillation. Complications of defibrillator im plantation have been associated mainly with transvenous lead insertion and have included pneumothorax, hemothorax, and cardiac tampon ade. 6-10 Difficulties in achieving venous access can prolong the procedure and occasionally result in failed ICD implantation. [11] [12] [13] In the long term, lead failure remains a major limitation in the use of ICDs, despite decades of innovations in lead de sign. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Lead failure either generates inappropri ate shocks or impedes appropriate therapy. [20] [21] [22] [23] Moreover, failed leads often require removal, a pro cedure that is associated with substantial mor bidity and mortality. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] If cardiac pacing is not necessary, there may be a clinical advantage in avoiding the use of transvenous electrodes. In this report, we describe the initial evaluation of an en tirely subcutaneous ICD system designed to avoid the need for the placement of sensing and therapy electrodes within or on the heart.
Me thods

Study Design
We report the results of two shortterm trials of a temporarily inserted subcutaneous ICD electrode system, followed by two trials of longterm sub cutaneous ICD implantation of a fully functional system. All the studies were sponsored by the manufacturer of the subcutaneous ICD, Cameron Health, and were designed by six of the academic investigators. The protocols were approved by the ethics committee at each participating institution and associated national and local regulatory agen cies. All study participants satisfied standard cri teria for ICD implantation 37 and provided written informed consent. Study data were collected by all the authors; device data were provided by engineers employed by the sponsor. The original man uscript was written by the first author with review and revi sion by all coauthors. All authors vouch for the accuracy and completeness of the data and the analyses.
Evaluation of Lead Configuration
From September 2001 through February 2004, we conducted the first shortterm defibrillation trial to identify the best electrode configuration among those tested for the subcutaneous ICD. Four elec trode configurations were selected on the basis of the use of specific anatomical landmarks: a left lateral pulse generator with an 8cm coil electrode positioned at the left parasternal margin, a left pectoral pulse generator with a 4cm coil elec trode at the left inferior sternum, a left pectoral pulse generator with an 8cm coil electrode curv ing from the left inferior sternum across to the inferior margin of the left sixth rib, and a left lateral pulse generator with a left parasternal 5cm 2 oval disk (Fig. 1) .
A total of 78 patients participated in this trial. Each patient underwent temporary subcutaneous implantation of one or more of the four device configurations evaluated and testing of the defi brillation threshold. The details of the protocol for defibrillationthreshold testing are described in the Supplementary Appendix, available with the full text of this article at NEJM.org. Testing was conducted in an interleaved fashion with the use of a Latin square design; the data were evaluated by means of analysis of variance. 38, 39 After comple tion of the study, all temporary subcutaneous de vices were explanted, and each patient underwent implantation of a conventional transvenous ICD.
Comparison of Temporary Subcutaneous ICD with Transvenous ICD
From April 2004 through June 2005, in a second shortterm trial involving 49 patients, we compared the best of the tested subcutaneous ICD systems in the first shortterm trial (Fig. 1A) with a trans venous ICD system. For each patient, both the subcutaneous and transvenous devices were im planted during the same procedure. Defibrilla tion thresholds were compared after both sys tems were in position and both surgical pockets had been closed. The system that was tested first was selected randomly. The protocol for defibril lationthreshold testing of the subcutaneous ICD was identical to that used in the first shortterm trial, as described in the Supplementary Appen dix. The statistical comparison of the defibrilla tion thresholds for the devices was performed with the use of a paired ttest. After completion of the study, the subcutaneous device was explanted.
Permanent Implantation
After the two shortterm trials, we performed two trials of permanent subcutaneous ICD implanta tion: a pilot trial involving 6 patients who under went implantation in July 2008 in New Zealand, followed by a trial involving 55 patients who un derwent implantation in New Zealand and Eu rope between December 2008 and February 2009. We identified candidates for subcutaneous ICD implantation among the patients who were re ferred for ICD implantation at each participating center. The inclusion criterion was a class I, IIa, or IIb indication for ICD therapy. 37 Exclusion cri teria were an estimated glomerular filtration rate of less than 30 ml per minute, a requirement for antibradycardia pacing, a history of ventricular tachycardia at rates slower than 170 beats per min ute, and documented ventricular tachycardia known to be reliably terminated with antitachycardia pac ing. The primary end point was successful imme diate conversion of two consecutive episodes of in duced ventricular fibrillation, each with a single 65J shock.
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LGen-S5 Disk The four lead systems that were tested to select the best of these candidates were a left lateral pulse generator with an 8-cm coil electrode positioned at the left parasternal margin, designated LGen-S8 (Panel A); a left pectoral pulse generator with a left parasternal 4-cm coil electrode at the inferior sternum, designated PGen-S4 (Panel B); a left pectoral pulse generator with an 8-cm coil electrode curving from the left inferior parasternal line across to the inferior margin of the left sixth rib, designated PGen-C8 (Panel C); and a left lateral pulse generator with a left parasternal 5-cm 2 oval disk, designated LGen-S5 (Panel D).
Subcutaneous ICD System
The subcutaneous ICD system that we tested in these studies consists of a 3mm tripolar para sternal electrode (polycarbonate urethane 55D), which is connected to an electrically active pulse generator. The electrode is positioned parallel to and 1 to 2 cm to the left of the sternal midline, and the pulse generator is positioned over the sixth rib between the midaxillary line and the anterior axillary line (Fig. 2) . The electrode has an 8cm shocking coil, flanked by two sensing electrodes. The distal sensing electrode is positioned adja cent to the manubriosternal junction, and the proximal sensing electrode is positioned adjacent to the xiphoid process. The insertion of the sub cutaneous ICD is guided exclusively by anatomical landmarks; no fluoroscopy is required. The surgi cal procedure and the devicetesting protocol dur ing implantation are described in the Supplemen tary Appendix. During device operation, the cardiac rhythm is detected by the two sensing electrodes or by either of the sensing electrodes and the pulse generator. The subcutaneous ICD system automatically se lects an appropriate vector for rhythm detection and for avoiding double QRS counting and Twave oversensing. Once signals have been validated as free of noise and double detection, feature analy sis and rate detection are used to sort rhythm type and determine the need for therapy. A condition al discrimination zone incorporating a feature extraction technique can be programmed between rates of 170 and 240 beats per minute to distin guish supraventricular tachycardia from ventric ular tachycardia and avoid inappropriate treatment of the former. Reconfirmation of ventricular tach yarrhythmia follows capacitor charging to avoid the delivery of shocks for nonsustained ventricu lar tachyarrhythmias. Testing of the device during implantation is done with the use of 65J shocks to ensure a margin of safety. However, after the device has been implanted, it delivers only 80J shocks. It can also reverse shock polarity auto matically if the initial shock is not successful. In addition, demand pacing at 50 beats per minute is available for 30 seconds after a shock, with the use of a 200mA biphasic transthoracic pulse. Pac ing is activated only after more than 3.5 seconds of postshock asystole.
All device settings are automated except for shock therapy (on/off), pacing after a shock (on/ off), conditional discrimination of supraventricu lar tachycardia (on/off), and the upperrate cutoff for the conditional shock zone (between 170 and 240 beats per minute). Data storage includes pre event electrograms and rhythm markers through event termination. Up to 24 treated episodes can be stored, with up to 120 seconds of data per episode.
R esult s
Evaluation of Lead Configuration
In the study comparing four lead configurations, the mean (±SD) age of the 78 patients was 61±11 years (range, 31 to 80), and 72 of the patients were men. The average weight was 82.4±15.2 kg (range, 53.0 to 143.5 [182±34 lb; range, 117 to 316]). The mean ejection fraction was 0.35±0.14 (range, 0.10 to 0.69). The mean defibrillation thresholds were 32.5±17.0 J (95% confidence interval [CI], 27.8 to 37.3) for configuration 1, 40.4±13.7 J (95% CI, 35.4 to 45.4) for configuration 2, 40.1±14.9 J (95% CI, 33.7 to 46.5) for configuration 3, and 34.3±12.1 J (95% CI, 28.8 to 39.8) for configuration 4 (Fig. 3A) . The left lateral pulse generator with the 8cm parasternal coil electrode (Fig. 1A) had the low est mean defibrillation threshold, although the differences among the configurations were not significant (P = 0.07 for all comparisons by analy sis of variance).
Temporary Subcutaneous ICD versus Transvenous ICD
In the study comparing the subcutaneous ICD with the transvenous ICD, the mean age of the 49 patients was 64±11 years (range, 42 to 79), and 47 of the patients were men. The average weight was 85.3±12.8 kg (range, 61.0 to 114.0 [188±28 lb; range, 134 to 251]). The mean ejection fraction was 0.37±0.13 (range, 0.19 to 0.70). The mean de fibrillation threshold was 11.1±8.5 J (95% CI, 8.6 to 13.5) with the transvenous ICD and 36.6±19.8 J (95% CI, 31.1 to 42.5) with the subcutaneous ICD (P<0.001) (Fig. 3B) . The transvenous device in one patient and the subcutaneous device in an other patient failed to terminate induced ventric ular fibrillation at maximum device output. In the patient whose subcutaneous ICD failed defi brillation testing, the parasternal electrode had been incorrectly positioned approximately 6 cm to the left of the sternum, beyond the left lateral margin of the heart.
Permanent Subcutaneous ICD Pilot Study
Six patients requiring ICD therapy underwent per manent subcutaneous device implantation in the pilot study. The mean age of the patients was 60±11 years (range, 46 to 72), with a mean weight of 99.0±12.0 kg (range, 87.0 to 114.0 [218±26 lb; range, 192 to 251] ). All the patients were men. The mean ejection fraction was 0.23±0.07 (range, 0.15 to 0.35). Five of the patients had coronary disease, and one had nonischemic cardiomyopa thy. Two had undergone previous cardiac surgery. One patient had a secondaryprevention indication, and five had a primaryprevention indication.
All six patients underwent successful implan tation of the subcutaneous ICD, and in all the patients, defibrillation with 65J submaximal shocks was successful during two consecutive epi sodes of induced ventricular fibrillation. A total of 18 episodes of ventricular fibrillation were in duced (with one patient having multiple episodes of nonsustained ventricular fibrillation terminat ing before shock delivery); all the episodes were appropriately detected. After 488±2 days of fol lowup (95 patientmonths of subcutaneous ICD therapy), no spontaneous episodes of ventricular tachycardia or ventricular fibrillation had oc curred in the six patients, and all were well, with no devicerelated complications or inappropri ate shocks. LGen-S8 PGen-S4 PGen-C8
LGen-Disk Panel A shows delivered defibrillation-threshold energies (measured in joules) in the four practical lead configurations that are described in Figure  1 , as tested during trials of acute defibrillation ranges involving 78 patients. The T bars indicate standard deviations. Panel B shows a comparison of paired defibrillation-threshold data for transvenous ICDs and subcutaneous ICDs in 49 consecutive patients during randomized testing. The subcutaneous ICD was as effective as a transvenous ICD for terminating induced ventricular fibrillation, although with a significantly higher mean (±SD) energy requirement (36.6±19.8 J vs. 11.1±8.5 J, P<0.001). In these tests, the transvenous ICD in one patient and the subcutaneous ICD in another patient failed to defibrillate induced ventricular fibrillation at maximum device output. In each of these two cases, 20 J was arbitrarily added to the highest energy tested to assign a defibrillation-threshold value. In the patient whose subcutaneous device failed defibrillation testing, the parasternal electrode had been incorrectly placed 6 cm lateral to the sternum.
trogram from one episode of induction and ter mination of ventricular fibrillation.
European Clinical Trial
For the European singlegroup clinical trial, 65 pa tients who presented for ICD implantation satis fied the enrollment criteria. Eight patients declined to participate in the study, and in two cases, the patient's physician opted for implantation of a transvenous ICD. Thus, 55 patients were enrolled in the trial, and all received a subcutaneous ICD. The clinical characteristics of the patients are shown in Table 1 . Defibrillation testing was not possible in two patients because of intraoperative hemodynamic instability in one patient and failure to induce ven tricular fibrillation in the other. Therefore, 53 pa tients were evaluated for sensing and defibrillation during implantation. Of 137 episodes of induced ventricular fibrillation, 100% were detected by the subcutaneous ICD. In 52 of the 53 patients who were tested (98%), two consecutive episodes of induced arrhythmia were successfully converted at 65 J. Among these 52 patients, conversion was achieved with standard polarity in 50 patients and with reverse polarity in 2 patients. In the 53rd patient, defibrillation at 65 J was achieved during the first induction but not during the second in duction. As specified by the protocol, this patient received a transvenous ICD. In another patient, it was necessary to reposition the electrode, which was initially inserted in an inappropriate location 6 cm from the midline. The mean time to delivery of a shock was 14.0±2.5 seconds. The mean dura tion of the procedure, which was performed for the first time by most of the practitioners, includ ing device insertion and at least two induction and termination tests, was 67±33 minutes. The procedure time was reduced to 55±23 minutes for practitioners who completed at least three im plantations.
After 10±1 months and 46 patientyears of fol lowup, 54 of 55 patients (98%) were alive. One death from renal failure occurred 6 months after device implantation in an 84yearold patient. Eighteen days before he died, the patient request ed that his subcutaneous ICD be turned off. A pocket infection developed in two patients; pocket revision was performed in one patient, and the other elected to discontinue defibrillator ther apy. There were no cases of pocket erosion. No lead fractures developed in any patient, and no generator migration occurred. Minor lead migra tion was noted during followup in two patients. The radiographs in Panels A and B show the locations of the electrode and pulse generator of a subcutaneous ICD in a 54-year-old man who was evaluated in the pilot study. Panel C shows an electrocardiogram of an episode of induced ventricular fibrillation and its termination in the patient. The subcutaneous ICD was being evaluated for primary prevention in the patient, who had coronary disease, New York Heart Association class II heart failure with an ejection fraction of 15%, and obstructive lung disease; the patient's weight was 92 kg (203 lb).
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Another three patients had parasternal lead dis lodgment due to inadequate anchoring of the distal tip of the electrode. In each of these pa tients, lead repositioning was required within a week after surgery. In another patient, lead dis lodgment occurred at 6 months, during vigorous physical activity.
In one patient, oversensing occurred because of inadequate placement of the electrode in the header block, resulting in inadequate contact with one of the sensing electrodes. This problem was addressed the day after surgery with reprogram ming of the detection vector rather than reopera tion. Inappropriate sensing due to muscle noise occurred in three patients; the problem was ad dressed with device reprogramming in all three cases. One patient who had received a new drug therapy had inappropriate sensing (double detec tion) after the narrow QRS complex in sinus rhythm changed to a right bundlebranch block during sinus tachycardia (150 beats per minute). During 3 months of further followup after the detection algorithm was revised, no inappropriate shocks occurred. No shocks were delivered inap propriately for atrial fibrillation, sinus tachycar dia, or supraventricular tachycardia at any time during the study when such episodes occurred at rates of more than 170 beats per minute.
A total of 12 episodes of spontaneous ventricu lar tachycardia were detected and successfully treated in three patients, including 1 episode after the abovementioned software revisions (see the figure in the Supplementary Appendix). All patients were treated before the onset of syncope, and there were no adverse events. One of these patients was successfully treated for repetitive ven tricular tachycardia ("VT storm"), including seven successive episodes of ventricular tachycardia.
Discussion
In the studies reported here, we describe the ini tial evaluation of an entirely subcutaneous ICD system. We identified a suitable device configura tion, assessed the defibrillation threshold of the device in comparison to that of the standard trans venous ICD, and conducted two small, single group trials of permanent device implantation. In the permanentimplantation studies, the sub cutaneous ICD successfully and consistently de tected and converted ventricular fibrillation that was induced during electrophysiological testing. The device also successfully detected and treated 12 episodes of spontaneous ventricular tachyar rhythmia that occurred in patients who were en rolled in the European clinical trial.
The goal of developing a subcutaneous ICD was to overcome some of the problems that are as sociated with transvenous leads in conventional ICDs. 3, [6] [7] [8] [9] [10] [11] 14, 15, 40 Such a device could potentially reduce or eliminate problems such as failure to achieve vascular access, intravascular injury, and lead failure requiring difficult procedures for ex traction and replacement. Additional potential benefits of such a device include the preservation of venous access for other uses and the avoidance of radiation exposure during fluoroscopy, which is required for transvenous ICD implantation. These benefits would be especially important for young patients, in whom leads may fail during the decades that therapy is needed. 41 The need for ICD systems that avoid the use of transvenous leads has been recognized previ ously, 42-49 and some earlier exploratory efforts led to the present work. 50,51 Some physicians have adapted existing technology to treat children with Our studies are preliminary, earlyphase trials that were primarily intended to show the feasibil ity of an entirely subcutaneous ICD. They pro vide limited information regarding the detection and conversion of ventricular tachyarrhythmia in the clinical setting, despite the demonstration of consistent detection and termination of ventricu lar fibrillation at the time of implantation. These studies cannot show whether subcutaneous ICDs are superior to conventional transvenous ICDs with respect to such characteristics as lead sta bility or failure. Indeed, the initial experience in cludes several cases of problems such as lead migration, lead dislodgment, and inappropriate sensing. With respect to each of these issues, the subcutaneous ICD system was adjusted shortly af ter implantation in an effort to improve the sys tem's reliability. Problems with lead dislodgment have led to the introduction of an anchoring sleeve and a new surgical technique. Inappropri ate sensing has been addressed through software revision, with no incidents in the 3 months after revision. However, these modifications will require further testing in additional groups of patients. Ultimately, the relative benefit of subcutaneous ICDs, as compared with transvenous ICDs, will need to be shown in large, longterm, random ized, prospective, multicenter clinical trials.
In addition, there are inherent limitations of this device design. Although transient postshock pacing is available, the subcutaneous ICD cannot provide longterm pacing. It is therefore not an alternative to transvenous ICDs when antibrady cardia pacing is required. Also, the subcutaneous ICD is not designed to treat patients with ventricu lar tachycardia at rates slower than 170 beats per minute. The lack of capability to provide anti tachycardia pacing may be a limitation in patients with frequent, recurrent, monomorphic ventricu lar tachycardia.
In conclusion, we found that in small, nonran domized studies, an entirely subcutaneous ICD system successfully and consistently detected and converted episodes of ventricular fibrillation that were induced during electrophysiological testing. It also successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachy arrhythmia.
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